Premium
Enantioselective CE analysis of hepatic ketamine metabolism in different species in vitro
Author(s) -
Schmitz Andrea,
Thormann Wolfgang,
Moessner Lone,
Theurillat Regula,
Helmja Kati,
Mevissen Meike
Publication year - 2010
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/elps.200900703
Subject(s) - enantioselective synthesis , in vitro , metabolism , ketamine , chemistry , drug metabolism , biology , pharmacology , biochemistry , neuroscience , catalysis
Ketamine, an injectable anesthetic and analgesic consisting of a racemic mixture of S ‐and R ‐ketamine, is routinely used in veterinary and human medicine. Nevertheless, metabolism and pharmacokinetics of ketamine have not been characterized sufficiently in most animal species. An enantioselective CE assay for ketamine and its metabolites in microsomal preparations is described. Racemic ketamine was incubated with pooled microsomes from humans, horses and dogs over a 3 h time interval with frequent sample collection. CE data revealed that ketamine is metabolized enantioselectively to norketamine (NK), dehydronorketamine and three hydroxylated NK metabolites in all three species. The metabolic patterns formed differ in production rates of the metabolites and in stereoselectivity of the hydroxylated NK metabolites. In vitro pharmacokinetics of ketamine N ‐demethylation were established by incubating ten different concentrations of racemic ketamine and the single enantiomers of ketamine for 8 min and data modeling was based on Michaelis–Menten kinetics. These data revealed a reduced intrinsic clearance of the S ‐enantiomer in the racemic mixture compared with the single S ‐enantiomer in human microsomes, no difference in equine microsomes and the opposite effect in canine microsomes. The findings indicate species differences with possible relevance for the use of single S ‐ketamine versus racemic ketamine in the clinic.